Human Recombinant DNA: Global Markets
Report Scope:
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.
Report Includes:
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.
Report Includes:
- 24 data tables and 8 additional tables
- An overview of the global market for human recombinant DNA
- Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for human recombinant DNA, based on product, application, and region
- Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
- Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi
CHAPTER 1 INTRODUCTION
Introduction
Study Goals and Objectives
Reasons for Doing the Study
Intended Audience
Scope and Format
Methodology
Market Estimates
Information Sources
Geographical Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 OVERVIEW
Homologous Recombination (HR)
Targets for Cancer Therapy
CHAPTER 4 IMPACT OF COVID-19 PANDEMIC
CHAPTER 5 MARKET DYNAMICS
Market Drivers
Increasing Incidences of Chronic Diseases
Growing Aging Population
Advancements in Manufacturing Technologies
Market Restraints
Price Controls
Entry of Biosimilars
Opportunities
Untapped Potential in Emerging Markets
CHAPTER 6 MARKET BREAKDOWN BY PRODUCT TYPE
Human Protein Replacements
Market Size and Forecast
Therapeutic Agents for Human Diseases
Market Size and Forecast
Vaccines
Types of Vaccines
Market Size and Forecast
CHAPTER 7 MARKET BREAKDOWN BY END USER
Biotechnology and Pharmaceutical Industry
Market Size and Forecast
Research Laboratories and Academic Institutes
Market Size and Forecast
CHAPTER 8 MARKET BREAKDOWN BY REGION
Global Market by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 9 COMPETITIVE LANDSCAPE
Overview
CHAPTER 10 COMPANY PROFILES
ABBVIE INC.
ALEXION PHARMACEUTICALS
AMGEN INC.
ELI LILLY
MERCK & CO. INC.
SANOFI S.A.
TAKEDA PHARMACEUTICAL CO LTD.
Introduction
Study Goals and Objectives
Reasons for Doing the Study
Intended Audience
Scope and Format
Methodology
Market Estimates
Information Sources
Geographical Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 OVERVIEW
Homologous Recombination (HR)
Targets for Cancer Therapy
CHAPTER 4 IMPACT OF COVID-19 PANDEMIC
CHAPTER 5 MARKET DYNAMICS
Market Drivers
Increasing Incidences of Chronic Diseases
Growing Aging Population
Advancements in Manufacturing Technologies
Market Restraints
Price Controls
Entry of Biosimilars
Opportunities
Untapped Potential in Emerging Markets
CHAPTER 6 MARKET BREAKDOWN BY PRODUCT TYPE
Human Protein Replacements
Market Size and Forecast
Therapeutic Agents for Human Diseases
Market Size and Forecast
Vaccines
Types of Vaccines
Market Size and Forecast
CHAPTER 7 MARKET BREAKDOWN BY END USER
Biotechnology and Pharmaceutical Industry
Market Size and Forecast
Research Laboratories and Academic Institutes
Market Size and Forecast
CHAPTER 8 MARKET BREAKDOWN BY REGION
Global Market by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 9 COMPETITIVE LANDSCAPE
Overview
CHAPTER 10 COMPANY PROFILES
ABBVIE INC.
ALEXION PHARMACEUTICALS
AMGEN INC.
ELI LILLY
MERCK & CO. INC.
SANOFI S.A.
TAKEDA PHARMACEUTICAL CO LTD.
LIST OF TABLES
Summary Table: Global Market for Human Recombinant DNA, by Region, Through 2027
Table 1: Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
Table 2: Cancer Statistics Across Major Asian Countries, by Cancer Site/Type, 2020
Table 3: Global Human Recombinant DNA Market, by Product Type, Through 2027
Table 4: Global Market for Human Protein Replacements, by Region, Through 2027
Table 5: Global Market for Therapeutic Agents for Human Diseases, by Region, Through 2027
Table 6: Vaccine Types
Table 7: Global Market for Vaccines, by Region, Through 2027
Table 8: Global Market for Human Recombinant DNA, by End User, Through 2027
Table 9: Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, by Region, Through 2027
Table 10: Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, by Region, Through 2027
Table 11: Global Market for Human Recombinant DNA, by Region, Through 2027
Table 12: North American Market for Human Recombinant DNA, by Product Type Through 2027
Table 13: North American Market for Human Recombinant DNA, by End User, Through 2027
Table 14: North American Market for Human Recombinant DNA, by Country, Through 2027
Table 15: European Market for Human Recombinant DNA, by Product Type, Through 2027
Table 16: European Human Recombinant DNA Market, by End User, Through 2027
Table 17: European Market for Human Recombinant DNA, by Country, Through 2027
Table 18: Asia-Pacific Market for Human Recombinant DNA, by Product Type, Through 2027
Table 19: Asia-Pacific Human Recombinant DNA Market, by End User, Through 2027
Table 20: Asia-Pacific Market for Human Recombinant DNA, by Country, Through 2027
Table 21: Japan: Total Number of New Cancer Cases in Both Genders, 2020
Table 22: RoW Market for Human Recombinant DNA, by Product Type, Through 2027
Table 23: RoW Market for Human Recombinant DNA, by End User, Through 2027
Table 24: Leading Market Players in the Human Recombinant DNA Market Ecosystem
Table 25: AbbVie Inc.: Business Segments
Table 26: AbbVie Inc.: Financial Performance, Through 2020
Table 27: Amgen: Financial Performance, Through 2020
Table 28: Eli Lilly: Business Segments
Table 29: Eli Lilly: Financial Performance, 2018-2020
Table 30: Sanofi: Business Segments
Table 31: Sanofi: Financial Performance, 2018-2020
Summary Table: Global Market for Human Recombinant DNA, by Region, Through 2027
Table 1: Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
Table 2: Cancer Statistics Across Major Asian Countries, by Cancer Site/Type, 2020
Table 3: Global Human Recombinant DNA Market, by Product Type, Through 2027
Table 4: Global Market for Human Protein Replacements, by Region, Through 2027
Table 5: Global Market for Therapeutic Agents for Human Diseases, by Region, Through 2027
Table 6: Vaccine Types
Table 7: Global Market for Vaccines, by Region, Through 2027
Table 8: Global Market for Human Recombinant DNA, by End User, Through 2027
Table 9: Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, by Region, Through 2027
Table 10: Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, by Region, Through 2027
Table 11: Global Market for Human Recombinant DNA, by Region, Through 2027
Table 12: North American Market for Human Recombinant DNA, by Product Type Through 2027
Table 13: North American Market for Human Recombinant DNA, by End User, Through 2027
Table 14: North American Market for Human Recombinant DNA, by Country, Through 2027
Table 15: European Market for Human Recombinant DNA, by Product Type, Through 2027
Table 16: European Human Recombinant DNA Market, by End User, Through 2027
Table 17: European Market for Human Recombinant DNA, by Country, Through 2027
Table 18: Asia-Pacific Market for Human Recombinant DNA, by Product Type, Through 2027
Table 19: Asia-Pacific Human Recombinant DNA Market, by End User, Through 2027
Table 20: Asia-Pacific Market for Human Recombinant DNA, by Country, Through 2027
Table 21: Japan: Total Number of New Cancer Cases in Both Genders, 2020
Table 22: RoW Market for Human Recombinant DNA, by Product Type, Through 2027
Table 23: RoW Market for Human Recombinant DNA, by End User, Through 2027
Table 24: Leading Market Players in the Human Recombinant DNA Market Ecosystem
Table 25: AbbVie Inc.: Business Segments
Table 26: AbbVie Inc.: Financial Performance, Through 2020
Table 27: Amgen: Financial Performance, Through 2020
Table 28: Eli Lilly: Business Segments
Table 29: Eli Lilly: Financial Performance, 2018-2020
Table 30: Sanofi: Business Segments
Table 31: Sanofi: Financial Performance, 2018-2020
LIST OF FIGURES
Summary Figure A: Global Market for Human Recombinant DNA, by Region, 2020–2027
Summary Figure B: Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 1: Global Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 2: Global Market for Human Recombinant DNA, by Product Type, 2020–2027
Figure 3: Global Market for Human Protein Replacements, 2020–2027
Figure 4: Global Market for Therapeutic Agents for Human Diseases, 2020–2027
Figure 5: Evolution of Vaccine Technologies
Figure 6: Global Market for Vaccines, 2020-2027
Figure 7: Global Market Shares of Human Recombinant DNA, by End User, 2021
Figure 8: Global Market for Human Recombinant DNA, by End User, 2020–2027
Figure 9: Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, 2020–2027
Figure 10: Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, 2020–2027
Figure 11: Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 12: North American Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 13: North American Market Shares of Human Recombinant DNA, by End User, 2021
Figure 14: North American Market Shares of Human Recombinant DNA, by Country, 2021
Figure 15: U.S. Market for Human Recombinant DNA, 2020–2027
Figure 16: Canadian Market for Human Recombinant DNA, 2020–2027
Figure 17: European Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 18: European Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 19: European Market Shares of Human Recombinant DNA, by Country, 2021
Figure 20: Geriatric Population in Germany, 2000-2030
Figure 21: German Market for Human Recombinant DNA, 2020–2027
Figure 22: U.K. Market for Human Recombinant DNA, 2020–2027
Figure 23: French Market for Human Recombinant DNA, 2020–2027
Figure 24: Italian Market for Human Recombinant DNA, 2020–2027
Figure 25: Spanish Market for Human Recombinant DNA, 2020–2027
Figure 26: Rest of Europe Market for Human Recombinant DNA, 2020–2027
Figure 27: Asia-Pacific Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 28: Asia-Pacific Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 29: Asia-Pacific Market Shares of Human Recombinant DNA, by Country, 2021
Figure 30: New Cancer Cases in China, 2020
Figure 31: Distribution of New Cancer Cases in China, 2020
Figure 32: Chinese Market for Human Recombinant DNA, 2020-2027
Figure 33: Japanese Market for Human Recombinant DNA, 2020-2027
Figure 34: Indian Market for Human Recombinant DNA, 2020–2027
Figure 35: Rest of Asia-Pacific Market for Human Recombinant DNA, 2020–2027
Figure 36: New Cancer Cases in Africa, 2020
Figure 37: RoW Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 38: RoW Market Shares of Human Recombinant DNA, by End User, 2021
Figure 39: AbbVie Inc.: Net Revenue, by Business Segment, 2020
Figure 40: AbbVie Inc.: Net Revenue, by Region, 2020
Figure 41: Amgen: Total Sales, by Product, 2020
Figure 42: Amgen: Total Revenue, by Region, 2020
Figure 43: Eli Lilly: Total Sales, by Product Segment, 2020
Figure 44: Eli Lilly: Total Revenue, by Region, 2020
Figure 45: Sanofi: Net Sales, by Business Segment, 2020
Figure 46: Sanofi: Net Sales, by Region, 2020
Summary Figure A: Global Market for Human Recombinant DNA, by Region, 2020–2027
Summary Figure B: Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 1: Global Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 2: Global Market for Human Recombinant DNA, by Product Type, 2020–2027
Figure 3: Global Market for Human Protein Replacements, 2020–2027
Figure 4: Global Market for Therapeutic Agents for Human Diseases, 2020–2027
Figure 5: Evolution of Vaccine Technologies
Figure 6: Global Market for Vaccines, 2020-2027
Figure 7: Global Market Shares of Human Recombinant DNA, by End User, 2021
Figure 8: Global Market for Human Recombinant DNA, by End User, 2020–2027
Figure 9: Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, 2020–2027
Figure 10: Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, 2020–2027
Figure 11: Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 12: North American Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 13: North American Market Shares of Human Recombinant DNA, by End User, 2021
Figure 14: North American Market Shares of Human Recombinant DNA, by Country, 2021
Figure 15: U.S. Market for Human Recombinant DNA, 2020–2027
Figure 16: Canadian Market for Human Recombinant DNA, 2020–2027
Figure 17: European Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 18: European Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 19: European Market Shares of Human Recombinant DNA, by Country, 2021
Figure 20: Geriatric Population in Germany, 2000-2030
Figure 21: German Market for Human Recombinant DNA, 2020–2027
Figure 22: U.K. Market for Human Recombinant DNA, 2020–2027
Figure 23: French Market for Human Recombinant DNA, 2020–2027
Figure 24: Italian Market for Human Recombinant DNA, 2020–2027
Figure 25: Spanish Market for Human Recombinant DNA, 2020–2027
Figure 26: Rest of Europe Market for Human Recombinant DNA, 2020–2027
Figure 27: Asia-Pacific Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 28: Asia-Pacific Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 29: Asia-Pacific Market Shares of Human Recombinant DNA, by Country, 2021
Figure 30: New Cancer Cases in China, 2020
Figure 31: Distribution of New Cancer Cases in China, 2020
Figure 32: Chinese Market for Human Recombinant DNA, 2020-2027
Figure 33: Japanese Market for Human Recombinant DNA, 2020-2027
Figure 34: Indian Market for Human Recombinant DNA, 2020–2027
Figure 35: Rest of Asia-Pacific Market for Human Recombinant DNA, 2020–2027
Figure 36: New Cancer Cases in Africa, 2020
Figure 37: RoW Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 38: RoW Market Shares of Human Recombinant DNA, by End User, 2021
Figure 39: AbbVie Inc.: Net Revenue, by Business Segment, 2020
Figure 40: AbbVie Inc.: Net Revenue, by Region, 2020
Figure 41: Amgen: Total Sales, by Product, 2020
Figure 42: Amgen: Total Revenue, by Region, 2020
Figure 43: Eli Lilly: Total Sales, by Product Segment, 2020
Figure 44: Eli Lilly: Total Revenue, by Region, 2020
Figure 45: Sanofi: Net Sales, by Business Segment, 2020
Figure 46: Sanofi: Net Sales, by Region, 2020
